Sophiris Bio (SPHS) Trading 2.2% Higher

Sophiris Bio Inc (NASDAQ:SPHS) traded up 2.2% during mid-day trading on Friday . The stock traded as high as $2.49 and last traded at $2.31. 206,600 shares traded hands during trading, an increase of 15% from the average session volume of 179,967 shares. The stock had previously closed at $2.26.

Several equities research analysts have issued reports on the stock. Maxim Group set a $6.00 price target on shares of Sophiris Bio and gave the stock a “buy” rating in a research note on Monday, October 2nd. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Sophiris Bio in a research note on Friday, November 10th. Finally, ValuEngine raised shares of Sophiris Bio from a “strong sell” rating to a “sell” rating in a research report on Friday, December 15th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Sophiris Bio has an average rating of “Buy” and a consensus target price of $6.25.

The company has a debt-to-equity ratio of 0.60, a current ratio of 13.37 and a quick ratio of 13.37. The company has a market cap of $69.56, a PE ratio of -18.77 and a beta of 2.03.

An institutional investor recently raised its position in Sophiris Bio stock. Vanguard Group Inc. increased its stake in Sophiris Bio Inc (NASDAQ:SPHS) by 1.0% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 731,437 shares of the biopharmaceutical company’s stock after acquiring an additional 7,600 shares during the period. Vanguard Group Inc. owned approximately 2.43% of Sophiris Bio worth $1,609,000 as of its most recent SEC filing. Institutional investors own 5.47% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Sophiris Bio (SPHS) Trading 2.2% Higher” was first published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at

Sophiris Bio Company Profile

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with's FREE daily email newsletter.

Leave a Reply